What You Will Learn

Please join Carterra at our upcoming symposium in Boston, MA.

You will spend the day learning about high-throughput drug discovery with some of the industry’s leading scientists. Our speakers will present new ways of looking at discovery, applications, and workflows, including HT-SPR. The topics you'll hear about include:

Machine Learning and AI Approaches for Protein Engineering
Emerging Targets for Oncology and Beyond
Engineering Bispecific and Multifunctional Antibodies
Characterization for Novel Biotherapeutics

Network with your peers. Lunch will be provided. Registration is required as seating is limited.

Companies presenting in 2025:

Agenda
9:45 – 10:00 AM	Arrive and Check-in
10:00 – 10:30 AM	Networking and Coffee/Tea
10:30 – 10:45 AM	Symposium Begins—Welcome
10:45 – 11:15 AM	Deborah Moshinsky, PhD, Director of Antibody Characterization & Validation, Institute for Protein Innovation High-throughput Recombinant Antibody Validation for Community Distribution
	Abstract: The Institute for Protein Innovation (IPI) is a non-profit research organization providing recombinant antibodies to the biomedical community against understudied targets. Antibodies are produced using a yeast display platform, and rigorous QC and validation are performed to ensure highest quality. High-throughput surface plasmon resonance (SPR) is performed to assess binding affinity and kinetics, alongside polyreactivity, flow cytometry, immunofluorescence (IF) and other application assay testing. Cross-reactivity analysis ensures specificity among related proteins. Validated antibodies are distributed via Addgene, enabling broad scientific impact. This presentation highlights high-throughput SPR and antibody characterization using the Glypican protein family as an example.
11:15 – 11:45 AM	Sasen Efrem, MS, Senior Scientist, Ordaos High-Throughput VHH Nanobody Discovery: Integrating Machine Learning with Rapid Cell-Free Expression
	Abstract: We combine machine learning and cell-free expression to rapidly develop and optimize VHH nanobodies, enabling the assessment of nearly 200 potential binders per day—from DNA to binding kinetics. Our ML-driven models propose novel CDR sequences predicted to enhance affinity and specificity, which are quickly synthesized and screened via surface plasmon resonance. This streamlined workflow initially identifies monomeric VHHs and then extends to bi-specific constructs by combining multiple binders. The resulting data is continually fed back into our machine learning pipeline, refining subsequent rounds of nanobody design. We will present data illustrating the speed, flexibility, and potential impact of this integrated approach on nanobody discovery for both therapeutic and diagnostic applications.
11:45 AM – 12:00 PM	Break
12:00 – 1:00 PM	Lunch and Networking
1:00 – 1:30 PM	Tina Cairns, PhD, Staff Scientist , University of Pennsylvania Evaluation of the human polyclonal antibody response against key epitopes in herpes simplex virus glycoproteins gD, gC and gE over time
	Abstract coming soon
1:30 – 2:00 PM	Nicholas Abuid, PhD, Field Application Scientist , Carterra Applications from mAbs to Fragment Screening, How Carterra LSA, LSA^XT and Ultra HT-SPR Platforms Enable Highly Parallel Analysis Advancing All Drug Discovery Modalities
	Abstract: Carterra’s LSA platforms have set the bar for throughput and scalability for biologics discovery and now extend to small molecule and fragment screening. The Ultra enables a transformative approach to library screening, highly parallel analysis, where many targets can be screened simultaneously against a library. Why run single campaigns when you can screen your entire target backlog simultaneously? This presentation will highlight three interesting application examples: the detailed kinetic characterization of human Fab fragments directly from bacterial extracts, the profiling of binding of TCRs to arrays of immobilized pMHCs, and fragment library screening.
2:00 – 2:30 PM	Awaiting Abstract
2:30 PM	Symposium Ends

What You Will Learn

Register Here

Agenda